참고문헌
- Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013;62:479-491. https://doi.org/10.1016/j.metabol.2012.07.024
- Berthold HK, Gouni-Berthold I. Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler Suppl 2013;14:1-5. https://doi.org/10.1016/j.atherosclerosissup.2012.10.037
- Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016 Sep 27 [Epub]. http://doi.org/10.1194/jlr.R071233.
- Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-614.
- Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:996-1001. https://doi.org/10.1161/ATVBAHA.114.304785
- Lim TS, Yun JS, Cha SA, et al. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med 2016;31:1110-1119. https://doi.org/10.3904/kjim.2016.030
- Lee HJ, Pae JC, Sung KC, et al. Distribution of serum lipoprotein(a) level and its association with other risk factors in apparently healthy Korean. Korean Circ J 2006;36:150-158. https://doi.org/10.4070/kcj.2006.36.2.150
- Haffner SM, Morales PA, Stern MP, Gruber MK. Lp(a) concentrations in NIDDM. Diabetes 1992;41:1267-1272. https://doi.org/10.2337/diab.41.10.1267
- Ding L, Song A, Dai M, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res 2015;56:920-926. https://doi.org/10.1194/jlr.P049015
- Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993;87:1135-1141. https://doi.org/10.1161/01.CIR.87.4.1135
- Marcovina SM, Albers JJ, Jacobs DR Jr, et al. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans: the CARDIA study. Arterioscler Thromb 1993;13:1037-1045. https://doi.org/10.1161/01.ATV.13.7.1037
- Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423. https://doi.org/10.1001/jama.2009.1063
- Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-1158. https://doi.org/10.1161/01.ATV.13.8.1139
- AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267. https://doi.org/10.1056/NEJMoa1107579
- Ko HS, Kim CJ, Ryu WS. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. J Cardiovasc Pharmacol 2005;46:405-411. https://doi.org/10.1097/01.fjc.0000175875.48167.c7